Compare FSUN & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | BHVN |
|---|---|---|
| Founded | 1892 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.0M | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | FSUN | BHVN |
|---|---|---|
| Price | $37.79 | $11.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $45.67 | $29.79 |
| AVG Volume (30 Days) | 148.6K | ★ 3.5M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.52 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $384,497,000.00 | N/A |
| Revenue This Year | $18.64 | N/A |
| Revenue Next Year | $49.01 | $2,219.74 |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $29.95 | $7.48 |
| 52 Week High | $45.32 | $44.28 |
| Indicator | FSUN | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 67.84 | 57.02 |
| Support Level | $33.41 | $8.29 |
| Resistance Level | $36.15 | $11.71 |
| Average True Range (ATR) | 0.95 | 0.72 |
| MACD | 0.66 | 0.47 |
| Stochastic Oscillator | 94.50 | 95.32 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.